Fundraising Fox
Outrun Therapeutics
Dundee, GB · 10 employees on LinkedIn · 3 known investors
Find your way into Outrun Therapeutics
Sign up to see every warm intro you have to Outrun Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Outrun Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Outrun Therapeutics is a preclinical biotech developing small molecule E3 ligase inhibitors to stabilise tumour suppressor proteins for treating cancer and other diseases. Its lead programme targets an E3 ligase in hard-to-treat solid tumours.
Founders & leadership
Investors · 3
How we know: M Ventures's portfolio page · Not right? Tell us
How we know: MC Healthcare Ventures's portfolio page · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountSeedApr 2024Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Companies House · registry record
View on Companies House ↗- Registered name
- OUTRUN THERAPEUTICS LIMITED
- Company number
- SC648164
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 26 Nov 2019
- Registered office
- Errol Road, Invergowrie, Dundee, DD2 5DA
- Nature of business (SIC)
- 86900 — Other human health activities
- Accounts
- last made up to 31 Dec 2025 · next due 30 Sept 2027
- Confirmation statement
- last made up to 12 Mar 2026 · next due 26 Mar 2027
Current officers · 4
- Bauke Anninga — director, appointed 27 Nov 2023
- Anthony Gerard Johnson — director, appointed 23 Sept 2022
- Christopher Roberts — director, appointed 14 Jul 2021
- Satpal Singh Virdee — director, appointed 24 Nov 2020
Source: Companies House public register · retrieved 30 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does Outrun Therapeutics do?
- Outrun Therapeutics is a preclinical biotech developing small molecule E3 ligase inhibitors to stabilise tumour suppressor proteins for treating cancer and other diseases. Its lead programme targets an E3 ligase in hard-to-treat solid tumours.
- Who founded Outrun Therapeutics?
- Outrun Therapeutics was founded by Satpal Virdee.
- Who are Outrun Therapeutics's investors?
- Outrun Therapeutics's investors include M Ventures, MC Healthcare Ventures, Diamond Edge Ventures.
- Where is Outrun Therapeutics headquartered?
- Outrun Therapeutics is headquartered in Dundee, GB.